Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: John Zwiener who wrote (27284)	1/7/1999 4:04:00 AM
From: Cheryl Galt	Read Replies (1) \| Respond to of 32384

Re: Lilly and the label extension approved for Evista. John, Lilly is one of Ligand's partners, but Evista is not one of Ligand's drugs. So no royalties will be coming to us. ---------------------- Lilly's Evista (Raloxifene) recently was approved for Osteoporosis. During testing for osteoporosis, results coincidentally suggested a possible benefit of reduced breast cancer risk, and the FDA is allowing them to say this on the label. Zeneca's similar drug, Tamoxifen, which has been used for over 20 years as THE standard adjuvant TREATMENT after breast cancer surgery, recently got a label extension for breast cancer PREVENTION from the FDA (though there is considerable controversy about this, and the jury is NOT out. I've gathered lots of data on this issue.) (BCCT trial - nsabp.pitt.edu Evista (raloxifene) and Tamoxifen are now going head-to-head to see which might be better for breast cancer prevention. (The just-being-launched STAR trial - 207.121.187.155 ) This is gorrilla-war competition for big bucks. Both drugs are currently on pharmacy shelves. Ligand's Phase II drug Targretin (if successful) might either compete with these gorillas, or synergize with them, in the breast cancer treatment/prevention market. ------------------- I hope this helps. I'm sure Henry can improve on this summary. Cheryl